|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001792,
umls-concept:C0004475,
umls-concept:C0005953,
umls-concept:C0023467,
umls-concept:C0030705,
umls-concept:C0038952,
umls-concept:C0040808,
umls-concept:C0205251,
umls-concept:C0439858,
umls-concept:C0523113,
umls-concept:C1707455,
umls-concept:C1947933
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2010-1-29
|
|
pubmed:abstractText |
In a phase III randomized trial, azacitidine significantly prolonged overall survival (OS) compared with conventional care regimens (CCRs) in patients with intermediate-2- and high-risk myelodysplastic syndromes. Approximately one third of these patients were classified as having acute myeloid leukemia (AML) under current WHO criteria. This analysis compared the effects of azacitidine versus CCR on OS in this subgroup.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:BackstromJayJ,
pubmed-author:BeachC LCL,
pubmed-author:DombretHervéH,
pubmed-author:FenauxPierreP,
pubmed-author:GattermannNorbertN,
pubmed-author:GermingUlrichU,
pubmed-author:GoreStevenS,
pubmed-author:Hellström-LindbergEvaE,
pubmed-author:ListAlan FAF,
pubmed-author:McKenzieDavidD,
pubmed-author:MuftiGhulam JGJ,
pubmed-author:SantiniValeriaV,
pubmed-author:SanzGuillermoG,
pubmed-author:SeymourJohn FJF,
pubmed-author:SilvermanLewis RLR,
pubmed-author:ZimmermanLindaL
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
562-9
|
|
pubmed:dateRevised |
2010-8-9
|
|
pubmed:meshHeading |
pubmed-meshheading:20026804-Aged,
pubmed-meshheading:20026804-Aged, 80 and over,
pubmed-meshheading:20026804-Antimetabolites, Antineoplastic,
pubmed-meshheading:20026804-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20026804-Azacitidine,
pubmed-meshheading:20026804-Blast Crisis,
pubmed-meshheading:20026804-Bone Marrow Cells,
pubmed-meshheading:20026804-Female,
pubmed-meshheading:20026804-Follow-Up Studies,
pubmed-meshheading:20026804-Humans,
pubmed-meshheading:20026804-International Agencies,
pubmed-meshheading:20026804-Leukemia, Myeloid, Acute,
pubmed-meshheading:20026804-Leukocyte Count,
pubmed-meshheading:20026804-Male,
pubmed-meshheading:20026804-Maximum Tolerated Dose,
pubmed-meshheading:20026804-Middle Aged,
pubmed-meshheading:20026804-Neoplasm Staging,
pubmed-meshheading:20026804-Prognosis,
pubmed-meshheading:20026804-Survival Rate,
pubmed-meshheading:20026804-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
|
|
pubmed:affiliation |
Service d'Hématologie Clinique, Hospital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris XIII, Bobigny, France. pierre.fenaux@avc.aphp.fr
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
